Key result
Statin use was associated with a significantly lower risk of recurrent VTE compared with no statin use (HR 0.74; 95% CI 0.68-0.80), with the benefit observed primarily in patients ≤80 years old.
Why the study?
Does statin therapy reduce the risk of recurrent hospitalised VTE in patients with a prior VTE?
Cohort (n=44,330)
Yes
Does statin therapy reduce the risk of recurrent hospitalised VTE in patients with a prior VTE?
Hazard Ratio: 0.74 (95% CI 0.68–0.8)
Absolute Event Rate: 24.4% vs 48.5%
Statin use is associated with a decreased risk of recurrent VTE in patients ≤80 years old, but may increase risk in those >80 years old.
Hypothesis-generating for statin use to prevent recurrent VTE in patients ≤80 years; prospective trials needed before clinical adoption.
OBJECTIVES: Statins may decrease the risk of primary venous thromboembolism (VTE), that is, deep vein thrombosis (DVT) and pulmonary embolism (PE) but the effect of statins in preventing recurrent VTE is less clear. The aim of this study was therefore to investigate the association between statin therapy and risk of recurrent VTE. DESIGN: A prospective cohort study. SETTING: All hospitals in Denmark. PARTICIPANTS: All patients with a hospital diagnosis of VTE in Denmark during 1997-2009 associated with a warfarin or heparin prescription were identified. MAIN OUTCOME MEASURES: Adjusted HR of recurrent hospitalised VTE (ie, fatal or non-fatal DVT or PE) associated with use of statins. RESULTS: 44 330 patients with VTE were included in the study. Of these 3914 were receiving statin therapy at baseline. Patients receiving statins were older (68±11 compared to 62±18 years), had more comorbidity and used more medications. The incidence rate for recurrent VTE was 24.4 (95% CI 22.8 to 26.2) per 1000 person-years among statin users and 48.5 (95% CI 47.4 to 49.7) per 1000 person-years among non-statin users. Statin use was associated with a significantly lower risk of a recurrent VTE, adjusted HR 0.74 (95% CI 0.68 to 0.80), compared with no statin use. The association between statin use and risk of recurrent VTE was significantly affected by age. Among younger individuals (≤80 years), statin use was associated with lower risk of recurrent VTE, HR 0.70 (95% CI 0.65 to 0.76) whereas in older individuals (>80 years) statin use was significantly associated with higher risk of recurrent VTE, HR 1.28 (95% CI 1.02 to 1.60), p for interaction=<0.0001. CONCLUSIONS: Statin use was associated with a decreased risk of recurrent VTE.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2013) conducted a cohort in Venous thromboembolism (VTE) (n=44,330). Statin therapy vs. No statin use was evaluated on Recurrent hospitalised VTE (fatal or non-fatal DVT or PE) (HR 0.74, 95% CI 0.68 to 0.80). Statin use was associated with a significantly lower risk of recurrent VTE compared with no statin use (HR 0.74; 95% CI 0.68-0.80), with the benefit observed primarily in patients ≤80 years old.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: